Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALYQ vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (first-line or after progression on crizotinib)
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Metabolized primarily by CYP3A4; also a substrate of P-glycoprotein. The major active metabolite (M4) is formed by CYP3A4 and contributes to clinical activity.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Approximately 30-40% bound to plasma proteins, primarily albumin.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water and tissues.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Oral bioavailability is approximately 80-90%.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: reduce dose to 300 mg on Day 1, then 150 mg daily for 4 days; not recommended in dialysis.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Not established; safety and efficacy in pediatric patients not determined.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
No specific dose adjustment; monitor renal function and adjust per renal criteria.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
No FDA black box warning.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Hepatotoxicity (elevated AST/ALT, bilirubin; monitor liver function),Interstitial lung disease/pneumonitis (monitor for pulmonary symptoms),Severe myalgia or creatine phosphokinase (CPK) elevation (monitor CPK levels),Bradycardia (monitor heart rate and blood pressure),Severe gastrointestinal adverse reactions (diarrhea, nausea, vomiting),Embryo-fetal toxicity (can cause fetal harm; advise contraception)
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
None known.
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
High-fat meals significantly reduce absorption of aliskiren. Administer with a low-fat meal or on an empty stomach, consistently. Avoid grapefruit juice as it may alter drug levels. Avoid potassium-rich foods in large amounts if taking with other drugs that raise potassium.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment. Pregnancy must be excluded before initiation and effective contraception used during therapy and for 1 month after discontinuation.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
ALYQ is excreted into human milk; M/P ratio is 0.85. Potential for serious adverse reactions in breastfed infants (renal toxicity, neutropenia). Decision: discontinue breastfeeding or discontinue ALYQ, considering importance of drug to mother.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Pregnancy contraindicated; no dose adjustments recommended as drug should not be used. In general, increased renal clearance during pregnancy may require dose adjustments; however, due to high teratogenicity, alternative agents are preferred.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
ALYQ (aliskiren) is a direct renin inhibitor used for hypertension. It should not be used with ACE inhibitors or ARBs due to increased risk of hypotension, hyperkalemia, and renal impairment. Avoid in pregnancy and severe renal impairment (e GFR <30 m L/min). Monitor serum potassium and renal function regularly. Administer with a low-fat meal or on an empty stomach to avoid reduced absorption.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Take this medication exactly as prescribed, usually once daily.,Do not take with high-fat meals as they decrease absorption.,Avoid potassium supplements and salt substitutes containing potassium.,Seek immediate medical attention if you experience signs of allergic reaction (hives, difficulty breathing, swelling of face/lips/tongue/throat).,Tell your doctor if you become pregnant or plan to become pregnant; this drug can cause fetal harm.,You may experience dizziness or lightheadedness; avoid driving until you know how this medication affects you.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALYQ vs ANEXSIA 7.5/650, answered by our medical review team.
ALYQ is a Unknown that works by ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALYQ and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALYQ is: Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALYQ and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALYQ is classified as Category C. ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Ris. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.